What is the appropriate management for a patient who is scoring +2 on the Richmond Agitation‑Sedation Scale?

Management of RASS +2 (Agitated Patient)

A patient with RASS +2 requires immediate assessment and treatment of pain first, followed by sedation with non-benzodiazepine agents as the preferred approach, targeting a goal RASS of -2 to 0.

Understanding RASS +2

A RASS score of +2 indicates agitation on the Richmond Agitation-Sedation Scale. According to ICU guidelines, any RASS score >0 (ranging from +1 to +4) defines an agitated patient who is "under-sedated" 1. This patient requires intervention to prevent harm to themselves, healthcare workers, and to optimize clinical outcomes.

Algorithmic Management Approach

Step 1: Assess and Treat Pain FIRST

This is the critical first step that is often missed. Before administering any sedatives:

• Assess pain using validated tools 1:

  • If patient can self-report: Use Numeric Rating Scale (NRS 0-10)
  • If unable to self-report: Use Behavioral Pain Scale (BPS) or Critical-Care Pain Observation Tool (CPOT)
  • Significant pain = NRS ≥4, BPS >5, or CPOT ≥3

• Treat pain within 30 minutes 1:

  • Pharmacologic: IV opioids as first-line for non-neuropathic pain
  • Non-pharmacologic: Relaxation therapy, repositioning, addressing discomfort sources
  • Then reassess pain

Rationale: The guidelines explicitly state "Treat pain first; then sedate" 1. Agitation is frequently driven by untreated pain, and sedating without addressing pain leads to worse outcomes.

Step 2: Address Reversible Causes of Agitation

Before pharmacologic sedation, systematically evaluate:

• Ventilator dyssynchrony - optimize ventilator settings
• Urinary retention or constipation - check and treat
• Delirium assessment - use CAM-ICU or ICDSC 1
• Drug withdrawal - particularly alcohol or benzodiazepines
• Hypoxia, hypoglycemia, or other metabolic derangements

Step 3: Pharmacologic Sedation (If Still RASS >0 After Pain Control)

Target sedation goal: RASS -2 to 0 (light sedation, patient purposely follows commands without agitation) 1, 2.

Preferred Sedative Agents:

Non-benzodiazepines are preferred over benzodiazepines 1:

• Dexmedetomidine
• Propofol
• Avoid benzodiazepines unless alcohol or benzodiazepine withdrawal is suspected 1

Rationale: Benzodiazepines are associated with increased delirium risk, prolonged mechanical ventilation, and worse outcomes 1, 2. The 2013 PAD guidelines strongly recommend non-benzodiazepine sedatives for improved short-term outcomes 1, 2.

For Acute Agitation Requiring Rapid Control:

If the patient poses immediate danger and rapid sedation is needed:

• Haloperidol 5 mg IM/IV OR Droperidol (if available and no QT prolongation risk) 3
• Midazolam 5 mg IM (faster onset than lorazepam) 4
• Combination therapy: Haloperidol 5 mg + Lorazepam 2-4 mg may produce more rapid sedation than monotherapy 3

Important caveat: These recommendations from emergency medicine guidelines 3 apply to undifferentiated agitated patients. In the ICU setting with established monitoring, the PAD guidelines' preference for non-benzodiazepines should guide ongoing management 1.

Step 4: Continuous Monitoring and Titration

• Reassess RASS every 4 hours minimum (or more frequently during active titration) 1
• If RASS remains >0: Reassess pain, then increase sedative dose as needed
• If RASS becomes <-2 (over-sedated): Hold sedatives until target achieved, then restart at 50% of previous dose 1
• Document sedation goals daily and adjust targets based on clinical needs 2, 5, 6

Step 5: Delirium Prevention and Management

Since agitation often coexists with or predicts delirium:

• Screen for delirium using CAM-ICU or ICDSC every shift 1

• Multicomponent non-pharmacologic interventions 2:

  • Reorient patient frequently
  • Provide eyeglasses, hearing aids
  • Optimize sleep (control light/noise, cluster care activities)
  • Early mobilization and exercise (strongly recommended) 1, 2
  • Minimize nocturnal stimuli

• Avoid antipsychotics prophylactically for delirium prevention 1

• Avoid rivastigmine 1

Common Pitfalls to Avoid

1. Sedating before assessing/treating pain - This is the most common error. Always address pain first 1.

2. Using benzodiazepines as first-line sedatives - Unless alcohol/benzodiazepine withdrawal is suspected, avoid benzodiazepines due to increased delirium risk and worse outcomes 1, 2.

3. Targeting deep sedation (RASS <-2) - Deep sedation is associated with prolonged mechanical ventilation, increased ICU length of stay, and worse long-term outcomes 1, 7, 2. Target light sedation (RASS -2 to 0) unless clinically contraindicated.

4. Not reassessing frequently enough - Sedation needs change rapidly in critical illness. Assess at least every 4 hours 1.

5. Ignoring reversible causes - Ventilator dyssynchrony, full bladder, constipation, and metabolic derangements commonly cause agitation and should be addressed before escalating sedation.

6. Forgetting delirium screening - Agitation and delirium frequently coexist. Screen systematically 1, 2.

Quality Metrics

Monitor these institutional metrics to ensure guideline adherence 1:

• % of time RASS assessments performed ≥4x/shift
• % of time patients achieve target sedation (RASS -2 to 0)
• % of time patients are under-sedated (RASS >0)
• % of time patients are over-sedated (RASS <-2)

Evidence Strength

These recommendations are based primarily on the 2013 Society of Critical Care Medicine PAD Guidelines published in Critical Care Medicine 1, which represent the highest quality guideline evidence available for ICU sedation management. The 2018 update 2 reinforces these principles with additional emphasis on light sedation and multicomponent delirium prevention strategies. While newer monitoring technologies exist 8, validated clinical scales like RASS remain the gold standard 7, 8.